Prostate cancer — all decisions

The Board denied earlier effective dates for the grant of service connection for chronic urethritis and left and right inguinal hernia repair, as there was no evidence of a claim prior to June 3, 2024. The claims for service connection for removal of left testicle, orchitis of right testicle, malignant prostate cancer with residual voiding dysfunction, compensable disability evaluation for chronic urethritis and left and right inguinal hernia repair were remanded for further development.

The Board denied the veteran's claims for increased ratings and initial compensable ratings for prostate cancer, erectile dysfunction, left lower extremity peripheral neuropathy, and right lower extremity peripheral neuropathy.

The Board granted service connection for ischemic heart disease and prostate cancer, due to herbicide agent exposure during the Veteran's service in Vietnam.

The Board granted service connection for prostate cancer, heart disease, and small intestine cancer based on herbicide exposure due to the Veteran's duties at Korat Royal Air Force Base.

The Board denied an initial compensable rating for bilateral sensorineural hearing loss and remanded the claims for service connection for prostate cancer, lumbosacral strain, and a higher rating for TBI.

The Veteran withdrew his appeals for service connection for prostate cancer and hypothyroidism.

The Board granted service connection for an acquired psychiatric disorder, to include PTSD and other specified trauma and stressor related disorder, but denied service connection for prostate cancer.

The Board denied the Veteran's claim for service connection for prostate cancer, finding no evidence to support a link between his condition and his active military service.

The appeal seeking entitlement to a total disability rating based on individual unemployability (TDIU) was dismissed due to an improper concurrent election of review options.

The Board denied higher ratings for obstructive sleep apnea, prostate cancer, and PTSD but granted an earlier effective date for TDIU and DEA.

The Veteran's prostate cancer residuals were granted a rating of 30 percent effective August 31, 2023.

The Board remands the issue of entitlement to service connection for prostate cancer, to include as due to exposure to herbicide agents and contaminated water at Camp Lejeune, for further development and an addendum medical opinion.

The Board denied service connection for prostate carcinoma and malignant neoplasm of intrapelvic lymph nodes, finding no evidence linking the conditions to active duty or exposure at Camp Lejeune.

The Board denied service connection for left and right lower extremity peripheral neuropathy, an increased rating for prostate cancer, and dismissed the appeal for special monthly compensation as moot.

The Board remands the claims for service connection for bladder cancer, diabetes mellitus, type II, and prostate cancer due to a need for further development of evidence.

The Board granted earlier effective dates for erectile dysfunction and special monthly compensation, but denied an earlier effective date for prostatectomy residual scars. The reduction in the rating from 100 percent to 20 percent for prostate cancer residuals was upheld.

The Board remands the issues of entitlement to an initial rating in excess of 10 percent for hypertension and an initial compensable rating for prostate cancer for further action by the agency of original jurisdiction.

The Board granted a 100 percent disability rating for the acquired psychiatric disorder and an effective date of August 3, 2018, for special monthly compensation based on aid and attendance.

The Board remands the claims for service connection for prostate cancer, hypertension, and diabetes mellitus type II due to duty-to-assist errors and a need for additional development of evidence related to in-service chemical exposures.

The Board denied a 100 percent rating for prostate cancer and granted a 10 percent rating from June 1, 2025.